降低TMIGD1会通过克罗恩病的BANF1-NF-κB通路加剧结肠炎和肠壁功能障碍
Longyuan Zhou1, Liguo Zhu1, Xiaomin Wu1
1Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
BMC medicine
|August 4, 2023
概括
含有跨膜和免疫球蛋白域蛋白1 (TMIGD1) 维护肠道屏障的完整性,并减少克罗恩病 (CD) 中的炎症. TMIGD1是CD的潜在治疗标,因为它的表达预测了治疗反应.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 克罗恩病 (CD) 的特点是肠道上皮屏障的破坏.
- 含有跨膜和免疫球蛋白域蛋白1 (TMIGD1) 是一种粘附分子,在肠道健康方面具有潜在的作用.
- 在CD中TMIGD1的功能及其与临床特征的关联在很大程度上是未知的.
研究的目的:
- 研究TMIGD1在克罗恩病中维持肠上皮质屏障完整性的作用.
- 在CD.的背景下探索TMIGD1功能的潜在机制.
- 为了确定TMIGD1表达是否可以预测CD患者的治疗反应.
主要方法:
- 1000IBD队列的多omics整合 (基因组学,转录组学,蛋白质组学).
- 通过细胞系,有机体和Tmigd1淘汰小鼠的细胞因子生产来评估炎症.
- 通过TEER,准细胞透性和AJC表达来评估上皮屏障完整性.
- 机理学研究包括共免疫沉和质谱学.
主要成果:
- 在CD患者和小鼠的炎症性肠粘膜中,TMIGD1被降低调节,并且与炎症特征负面相关.
- TMIGD1倒置损害了肠道屏障的完整性,并诱导了促炎性细胞因子的产生.
- TMIGD1与BANF1直接相互作用,抑制NF-κB激活,恢复屏障功能并减少炎症.
- 在CD患者中,TMIGD1表达预测了对抗TNF治疗的反应.
结论:
- TMIGD1在维持肠道屏障完整性和抑制炎症方面发挥着至关重要的作用.
- TMIGD1 作为克罗恩病的潜在治疗点.
- TMIGD1表达是CD中抗TNF治疗反应的预测生物标志物.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
355
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
355
Inflammatory Bowel Disease II: Crohn's Disease
291
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
291
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Inflammatory Bowel Disease I: Ulcerative Colitis
215
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
215
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K


